SM
EDIT icon

Sabby Management’s Editas Medicine EDIT Stock Holding History

Sabby Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-881
Closed -$291K – 185
2017
Q2 		$291K Buy
881
+97
+12% +$1.75K 0.02% 163
2017
Q1 		$1.75M Buy
+784
New +$16.2K 0.09% 101

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sabby Management's EDIT Position: Q3 2017 in Review

Sabby Management sold out of Editas Medicine (EDIT) in Q3 2017, closing a stake of 85,000 shares — an estimated $1.43M sold.

Sabby Management first reported a position in EDIT in Q3 2016 and held it in 4 quarters. The position peaked at $2.02M in Q1 2017. 116 funds tracked by Wall St. Rank hold EDIT as of Q3 2017.

  • Sabby Management reported no remaining Editas Medicine position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 85,000 Editas Medicine shares in Q3 2017, an estimated $1.43M.
  • Sabby Management first reported a position in Editas Medicine in Q3 2016 and held it in 4 quarters.
  • Sabby Management's Editas Medicine position peaked at $2.02M in Q1 2017.
  • 116 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.